MAP2K7 and plasma cell myeloma: B7-H1 expression was enhanced on malignant plasma cells from multiple myeloma patients by IFN-γ and Toll-like receptor stimulation via MEK/ERK-dependent and MyD88/TRAF6-dependent pathways and can inhibit T-cell responses [11].